Prospective, longitudinal, multinational, observational study that will collect data on how patients with peripheral T-cell lymphoma (PTCL) are treated in academic and community practices.

The COMPLETE registry is a prospective, longitudinal, multinational, observational study that will collect data on how patients with peripheral T-cell lymphoma (PTCL) are treated in academic and community practices. The registry will enroll newly-diagnosed patients with PTCL treated with a variety of regimens. The COMPLETE registry is designed to better understand PTCL patient characteristics, treatments, and outcomes to help design and understand future clinical trials.

Inclusion Criteria:

• Patient is newly diagnosed with Peripheral T-cell Lymphoma (PTCL):

  • Aggressive natural killer (NK)-cell leukemia
  • Adult T-cell lymphoma/leukemia (human T-cell leukemia virus [HTLV] 1+)
  • Angioimmunoblastic T-cell lymphoma
  • Anaplastic large cell lymphoma (ALCL), primary systemic type (ALK+, ALK-)
  • PTCL, not otherwise specified (NOS)
  • T/NK-cell lymphoma, nasal type
  • Enteropathy-type intestinal lymphoma
  • Hepatosplenic T-cell lymphoma
  • Subcutaneous panniculitis T-cell lymphoma
  • Transformed mycosis fungoides (at diagnosis of transformation)
  • T-cell prolymphocytic leukemia (T-PLL)
  • Cutaneous gamma/delta (γ/δ) T-cell lymphoma
  • Cutaneous aggressive CD8+ T-cell lymphoma
  • Hematodermic neoplasms (blastic plasmacytoid dendritic cell neoplasm)
  • Systemic Epstein Barr Virus (EBV)+ T-cell lymphomas (T-cell lymphoproliferative disorders of childhood)
  • Other T-Cell lymphomas that are not listed in the Exclusion Criteria

• Patient gives written informed consent

Exclusion Criteria:

• Patient has other T- or NK-cell malignancies including:

  • Precursor T/NK neoplasms
  • T-cell large granular lymphocytic leukemia
  • Mycosis fungoides, other than transformed mycosis fungoides
  • Sézary syndrome
  • Primary cutaneous CD30+ disorders: ALCL and lymphomatoid papulosis

Patients will be enrolled from academic and community cancer centers in the United States, France, Germany, Italy and Japan.